Form 4: AEON Biopharma Officer Boosts Stake with RSU Grants

AEON Biopharma's Principal Accounting Officer, Jennifer Sy, increased her beneficial ownership through significant restricted stock unit grants and modifications.

Summary

• Jennifer Sy, Principal Accounting Officer of AEON Biopharma, Inc., reported changes in her beneficial ownership of Class A Common Stock.
• On February 17, 2026, Sy was granted 575,000 restricted stock units (RSUs) which vest in substantially equal installments over four years, subject to continued service.
• On March 4, 2026, 925,925 outstanding cash-settled restricted stock units, originally granted on May 21, 2025, were modified to be settled in stock instead of cash.
• These modified RSUs also vest in substantially equal installments over four years from their original grant date, subject to continued service.
• Following these transactions, Sy's direct beneficial ownership of Class A Common Stock increased to 1,501,176 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies increased insider ownership and alignment of executive incentives with shareholder value, which is generally favorable.

Positives

• Increased beneficial ownership by a key executive, aligning management interests with shareholders.
• The modification of cash-settled RSUs to stock-settled RSUs further ties executive compensation to the company's stock performance.

Risks

• The value of the restricted stock units is subject to the future performance of AEON Biopharma's Class A Common Stock.
• Vesting of the RSUs is contingent upon continued service, posing a risk of forfeiture if employment ceases.

Future Outlook

The vesting schedules for the restricted stock units extend over the next four years, indicating a long-term incentive structure for the Principal Accounting Officer, contingent on continued employment.

Industry Context

StockSavvy.ai notes that insider acquisitions of equity awards, particularly restricted stock units, are a common mechanism for executive compensation and serve to align management's long-term interests with those of shareholders. This type of filing provides transparency into executive incentive structures within the biopharmaceutical industry.

Comparison to Industry Standards

• This RSU grant and modification structure is consistent with common executive compensation practices in the biotechnology and pharmaceutical sectors.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) frequently utilize similar long-term equity incentives for their executives to promote retention and performance alignment.
• The vesting schedule over four years is a standard industry practice designed to encourage sustained performance and commitment.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to higher equity ownership.
• Employees: The RSU grants serve as a long-term incentive for the Principal Accounting Officer, potentially signaling stability in key management roles.

Next Steps

• Vesting of 575,000 restricted stock units in substantially equal installments on the first, second, third, and fourth anniversaries of February 17, 2026.
• Vesting of 925,925 stock-settled restricted stock units in substantially equal installments on the first, second, third, and fourth anniversaries of May 21, 2025.

Key Dates

Keywords

AEON Biopharma, AEON, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Award, Beneficial Ownership, Jennifer Sy, Principal Accounting Officer